MPT0G066, a novel anti-mitotic drug, induces JNK-independent mitotic arrest, JNK-mediated apoptosis, and potentiates antineoplastic effect of cisplatin in ovarian cancer

Scientific Reports

Volumn 6, Issue , 2016, Pages

  Huang, Han Li ^a   Chao, Min Wu ^a   Li, Ya Chi ^b   Chang, Li Hsun ^b   Chen, Chun Han ^c   Chen, Mei Chuan ^a   Cheng, Chun Chun ^a   Liou, Jing Ping ^a   Teng, Che Ming ^b   Pan, Shiow Lin ^a,c  

^a TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^c TAIPEI MEDICAL UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BCL2 PROTEIN, HUMAN; CISPLATIN; MITOGEN ACTIVATED PROTEIN KINASE KINASE 4; PROTEIN BCL 2; SULFONAMIDE;

ANIMAL; APOPTOSIS; DRUG EFFECT; DRUG RESISTANCE; DRUG SCREENING; FEMALE; HUMAN; METABOLISM; MITOSIS; OVARY TUMOR; PATHOLOGY; PHOSPHORYLATION; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; CISPLATIN; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; MAP KINASE KINASE 4; MITOSIS; OVARIAN NEOPLASMS; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-BCL-2; SULFONAMIDES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84982181933     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep31664     Document Type: Article

References (23)

1. Jelovac, D., Armstrong, D. K. Recent progress in the diagnosis and treatment of ovarian cancer. CA Cancer J. Clin. 61, 183-203 (2011).
2. Karst, A. M., Drapkin, R. Ovarian cancer pathogenesis: a model in evolution. J. Oncol. 2010, 932371 (2010).
3. Dhanasekaran, D. N., Reddy, E. P. JNK signaling in apoptosis. Oncogene 27, 6245-6251 (2008).
4. Lopez-Bergami, P. The role of mitogen-and stress-activated protein kinase pathways in melanoma.Pigment Cell Melanoma Res 24, 902-921 (2011).
5. Wang, T. H. et al. Microtubule-interfering agents activate c-Jun N-terminal kinase/stress-activated protein kinase through both Ras and apoptosis signal-regulating kinase pathways.J. Biol. Chem. 273, 4928-4936 (1998).
6. Fan, M. et al. Vinblastine-induced phosphorylation of Bcl-2 and Bcl-XL is mediated by JNK and occurs in parallel with inactivation of the Raf-1/MEK/ERK cascade. J. Biol. Chem. 275, 29980-29985 (2000).
7. Kolomeichuk, S. N., Terrano, D. T., Lyle, C. S., Sabapathy, K., Chambers, T. C. Distinct signaling pathways of microtubule inhibitors-vinblastine and Taxol induce JNK-dependent cell death but through AP-1-dependent and AP-1-independent mechanisms, respectively. FEBS J. 275, 1889-1899 (2008).
8. Jackson, J. R., Patrick, D. R., Dar, M. M., Huang, P. S. Targeted anti-mitotic therapies: can we improve on tubulin agents? Nat. Rev. Cancer 7, 107-117 (2007).
9. Mollinedo, F., Gajate, C. Microtubules, microtubule-interfering agents and apoptosis. Apoptosis 8, 413-450 (2003).
10. Agarwal, R., Kaye, S. B. Ovarian cancer: strategies for overcoming resistance to chemotherapy. Nat. Rev. Cancer 3, 502-516 (2003).
11. Lai, M.-J. et al. N-Sulfonyl-aminobiaryls as Antitubulin Agents and Inhibitors of Signal Transducers and Activators of Transcription 3 (STAT3) Signaling. J. Med. Chem. 58, 6549-6558 (2015).
12. Wang, V. et al. Ovarian cancer is a heterogeneous disease. Cancer Genet. Cytogenet. 161, 170-173 (2005).
13. Friedlander, M. L. et al. Influence of cellular DNA content on survival in advanced ovarian cancer. Cancer Res. 44, 397-400 (1984).
14. Rodenburg, C. J., Cornelisse, C. J., Heintz, P. A., Hermans, J., Fleuren, G. J. Tumor ploidy as a major prognostic factor in advanced ovarian cancer. Cancer 59, 317-323 (1987).
15. Kihana, T. et al. High incidence of p53 gene mutation in human ovarian cancer and its association with nuclear accumulation of p53 protein and tumor DNA aneuploidy. Jpn. J. Cancer Res. 83, 978-984 (1992).
16. Godwin, A. K. et al. High resistance to cisplatin in human ovarian cancer cell lines is associated with marked increase of glutathione synthesis. Proc. Natl. Acad. Sci. USA 89, 3070-3074 (1992).
17. Hills, C. A. et al. Biological properties of ten human ovarian carcinoma cell lines: calibration in vitro against four platinum complexes. Br. J. Cancer 59, 527-534 (1989).
18. Castedo, M. et al. Cell death by mitotic catastrophe: a molecular definition. Oncogene 23, 2825-2837 (2004).
19. Lei, K., Davis, R. J. JNK phosphorylation of Bim-related members of the Bcl2 family induces Bax-dependent apoptosis. Proc. Natl. Acad. Sci. USA 100, 2432-2437 (2003).
20. Miyamoto-Yamasaki, Y., Yamasaki, M., Tachibana, H., Yamada, K. Induction of endoreduplication by a JNK inhibitor SP600125 in human lung carcinoma A 549 cells. Cell Biol. Int. 31, 1501-1506 (2007).
21. Moon, D. O. et al. JNK inhibitor SP600125 promotes the formation of polymerized tubulin, leading to G2/M phase arrest, endoreduplication, and delayed apoptosis. Exp. Mol. Med. 41, 665-677 (2009).
22. Kim, J. A., Lee, J., Margolis, R. L., Fotedar, R. SP600125 suppresses Cdk1 and induces endoreplication directly from G2 phase, independent of JNK inhibition. Oncogene 29, 1702-1716 (2010).
23. Wang, T. H. et al. Microtubule dysfunction induced by paclitaxel initiates apoptosis through both c-Jun N-terminal kinase (JNK)-dependent and-independent pathways in ovarian cancer cells. J. Biol. Chem. 274, 8208-8216 (1999).